Table 2.
CXC chemokine and receptor expression in primary PC.
| CXC chemokine/receptor | N0 (n = 342) | N1 (n = 77) | N0 vs. N1 | |
|---|---|---|---|---|
| Transcript per million (Lower quartile—upper quartile) | (p-value) | |||
| ELR− Chemokine | CXCL4 | −0.46 (−0.46 to 0.10) | −0.46 (−0.46 to 0.31) | 0.0639 |
| CXCL9 | −0.29 (−0.45 to −0.01) | −0.12 (−0.39 to −0.65) | 0.0005 | |
| CXCL10 | −0.30 (−0.50 to 0.03) | 0 (−0.38 to 0.62) | <0.0001 | |
| CXCL11 | −0.36 (−0.54 to 0.11) | −0.13 (−0.42 to 0.32) | 0.0013 | |
| CXCL12 | −0.19 (−0.56 to 0.21) | −0.25 (−0.67 to 0.12) | 0.1330 | |
| CXCL13 | −0.24 (−0.27 to −0.13) | −0.23 (−0.26 to −0.07) | 0.2210 | |
| CXCL16 | −0.06 (−0.67 to 0.50) | 0.11 (−0.72 to 0.64) | 0.8300 | |
| ELR− Chemokine | CXCR3 | −0.26 (−0.49 to 0.04) | −0.09 (−0.49 to 0.87) | 0.0161 |
| Receptor | CXCR4 | −0.26 (−0.55 to0.16) | −0.18 (−0.53 to 0.67) | 0.0502 |
| CXCR5 | −0.24 (−0.30 to −0.13) | −0.21 (−0.29 to 0.06) | 0.0130 | |
| CXCR6 | −0.20 (−0.48 to 0.22) | −0.06 (−0.51 to 0.40) | 0.3760 | |
| CXCR7 | −0.22 (−0.48 to 0.18) | −0.11 (−0.43 to 0.65) | 0.0487 | |
| ELR+ Chemokine | CXCL1 | −0.29 (−0.42 to 0) | −0.32 (−0.43 to −0.11) | 0.4960 |
| CXCL2 | −0.25 (−0.31 to −0.03) | −0.28 (−0.34 to −0.15) | 0.1090 | |
| CXCL3 | −0.21 (−0.26 to −0.03) | −0.23 (−0.26 to −0.12) | 0.2320 | |
| CXCL5 | −0.25 (−0.29 to −0.11) | −0.28 (−0.30 to −0.21) | 0.0134 | |
| CXCL6 | −0.26 (−0.43 to 0.11) | −0.30 (−0.49 to 0.02) | 0.1170 | |
| CXCL7 | −0.11 (−0.11 to −0.04) | −0.11 (−0.11 to −0.02) | 0.1790 | |
| CXCL8 | −0.26 (−0.40 to 0.08) | −0.34 (−0.45 to −0.15) | 0.0136 | |
| ELR+ Chemokine | CXCR1 | −0.29 (−0.47 to 0.09) | −0.42 (−0.50 to −0.23) | 0.0011 |
| Receptor | CXCR2 | −0.28 (−0.50 to 0.17) | −0.39 (−0.55 to −0.09) | 0.0380 |
The CXC chemokine/receptor gene expression levels were compared between lymph node metastasis-negative (N0; n = 342) and lymph node metastasis-positive (N1; n = 77) patients. Statistically significant differences in mRNA expression between the groups were identified using Mann–Whitney's U-test after confirmation of non-normal distributions.